VEGFA and acute kidney injury: It has been widely recognized that systemically administrated anti-VEGF agents are linked to increased risks of cardiovascular events (7) and renal adverse events (AEs), including proteinuria, acute kidney injury (AKI), glomerular disease, and thrombotic microangiopathy (TMA) (8–10).